Drug intelligence / Profile preview

UCT-MSC + biomaterials

Development stage: Preclinical
Lead developer: Vitti Labs
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intranasal, Intrathecal, Intraarticular

Overview

UCT-MSC + biomaterials is a cell therapy candidate being developed by Vitti Labs for the treatment of Crohn's disease, Duchenne muscular dystrophy (DMD), and autism. The product consists of mesenchymal stem cells (MSCs) harvested from umbilical cord tissue, which are integrated with a biomaterial scaffold or delivery system. This combination is designed to leverage the anti-inflammatory and tissue-repair capabilities of MSCs while using biomaterials to enhance cell retention and therapeutic efficacy. The program is currently in the IND-enabling phase, with the sponsor working toward filing Investigational New Drug applications for its lead indications.

Other names: umbilical cord tissue-derived mesenchymal stem cells + biomaterialsUCT-MSC plus biomaterials

Beyond the preview

Go deeper on UCT-MSC + biomaterials.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCT-MSC + biomaterials.

Explore the full profile